logo
Sign in

Larimar Therapeutics

BALA CYNWYD, PA · Founded 2005 · Biotech · Public

Small molecule therapeutics for rare genetic diseases

Claim this profile

Follows are private to you and power your alerts

Updated · larimartx.com

Sector
Biotech
Headquarters
BALA CYNWYD, PA
Founded
2005
Latest Form D
$80M, Jun 2020
Total capital
$201M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$201M
6 Form D · last Jun 2020
77 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
7
33 pending · first 2024
Rank in peer group#213 of 1449

Capital timeline

201020122014201620182020FEDERAL ↑EQUITY ↓Cumulative $201M4th Form D$21.8M5th Form D$82.1M
201020122014201620182020FEDERAL ↑EQUITY ↓Cumulative $201M4th Form D$21.8M5th Form D$82.1M

Latest events

  • Private capital raisedForm D · SEC · 6th filing$80M
  • Private capital raisedForm D · SEC · 5th filing$82.1M
  • Private capital raisedForm D · SEC · 4th filing$21.8M
  • Private capital raisedForm D · SEC · 3rd filing$3M
  • Private capital raisedForm D · SEC · 2nd filing$6.1M
  • Private capital raisedForm D · SEC · 1st filing$8.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#213 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Carole Ben Maimon, MDExecutive Officer, DirectorNamed in SEC Form D filings
  • Frank E. ThomasDirectorNamed in SEC Form D filings
  • Jonathan LeffDirectorNamed in SEC Form D filings
  • Joseph TruittDirectorNamed in SEC Form D filings
  • Michael CelanoExecutive OfficerNamed in SEC Form D filings
  • Peter BarrettDirectorNamed in SEC Form D filings
Show all 8 people
  • Thomas O. DanielDirectorNamed in SEC Form D filings
  • Thomas HamiltonDirectorNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 40
  • PendingMethods For Quantifying Frataxin ActivityUSPTOApplication 19292376
  • GrantedMethods For Quantifying Frataxin ActivityUSPTOUS 12,411,145
  • PendingMethods Of Treating Friedreich's AtaxiaUSPTOApplication 19051988
Show all 40 patent records
  • Methods For Quantifying Frataxin ActivityApr 23, 2026 · Application 19292376Pending
  • Methods For Quantifying Frataxin ActivitySep 9, 2025 · US 12,411,145Granted
  • Methods Of Treating Friedreich's AtaxiaSep 4, 2025 · Application 19051988Pending
  • Pharmaceutical Composition Comprising Frataxin Fusion Protein And Methods Of Use ThereofAug 19, 2025 · US 12,390,509Granted
  • Molecules For Organelle-specific Protein DeliveryJul 8, 2025 · US 12,351,611Granted
  • Molecules For Organelle-specific Protein DeliveryMar 13, 2025 · Application 18886511Pending
  • Methods For Treating Myelin Associated Diseases And Mitochondria Associated DiseasesOct 17, 2024 · Application 18433336Pending
  • Molecules For Organelle-specific Protein DeliverySep 17, 2024 · US 12,091,437Granted
  • Methods For Quantifying Frataxin ActivityMay 21, 2024 · US 11,988,675Granted
  • Methods For Treating Myelin Associated Diseases And Mitochondria Associated DiseasesMay 7, 2024 · US 11,976,100Granted
  • Frataxin-sensitive Lipid Markers For Monitoring Frataxin Replacement TherapyMay 2, 2024 · Application 18315445Pending
  • Molecules For Organelle-specific Protein DeliveryFeb 6, 2024 · US 11,891,420Granted
  • Frataxin-sensitive Markers For Monitoring Frataxin-replacement TherapyNov 9, 2023 · Application 18296966Pending
  • Use Of Frataxin For Treating Leigh Syndrome, French Canadian TypeDec 1, 2022 · Application 17627638Pending
  • Frataxin-sensitive Markers For Determining Effectiveness Of Frataxin Replacement TherapyDec 3, 2020 · Application 16864125Pending
  • Frataxin-sensitive Markers For Monitoring Progression And Treatment Of Leigh SyndromeApplication 63350320Pending
  • Frataxin-sensitive Lipid Markers For Monitoring Frataxin Replacement TherapyApplication 63340412Pending
  • Frataxin-sensitive Markers For Monitoring Frataxin-replacement TherapyApplication 63328238Pending
  • Pharmaceutical Composition Comprising Frataxin Fusion Protein And Methods Of Use ThereofApplication PCTUS2021063163Pending
  • Methods For Treating Myelin Associated And Mitochondria Associated DiseasesApplication PCTUS2021030348Pending
  • Molecules For Organelle-specific Protein DeliveryApplication PCTUS2021024534Pending
  • Pharmaceutical Composition Comprising Frataxin Fusion Protein and Methods of Use ThereofApplication 63124801Pending
  • Methods For Quantifying Frataxin ActivityApplication PCTUS2020062355Pending
  • Use Of Frataxin For Treating Leigh Syndrome, French Canadian TypeApplication PCTUS2020042683Pending
  • Slirp Fusion Proteins And Use Thereof For Treating Leigh SyndromeApplication PCTUS2020042685Pending
  • Methods For Treating Myelin Associated Diseases And Mitochondria Associated DiseasesApplication 63018451Pending
  • Frataxin-sensitive Markers For Determining Effectiveness Of Frataxin Replacement TherapyApplication PCTUS2020030884Pending
  • Methods Of Treating Friedreich's AtaxiaApplication PCTUS2025059983Pending
  • Molecules For Organelle-specific Protein DeliveryApplication 63000138Pending
  • Methods Of Treating Friedreich's AtaxiaApplication 63890214Pending
  • Methods Of Treating Friedreich's Ataxia In Pediatric SubjectsApplication 63799217Pending
  • Methods Of Treating Friedreich's AtaxiaApplication PCTUS2025015601Pending
  • Methods Of Treating Friedreich's Ataxia In Pediatric SubjectsApplication 63734723Pending
  • Methods Of Treating Friedreich's AtaxiaApplication 63734718Pending
  • Methods Of Treating Friedreich’s AtaxiaApplication 63734702Pending
  • Methods Of Treating Friedreich’s AtaxiaApplication 63718993Pending
  • Methods Of Treating Friedreich’s AtaxiaApplication 63655286Pending
  • Methods Of Treating Friedreich’s AtaxiaApplication 63552633Pending
  • Frataxin-sensitive Markers For Monitoring Progression And Treatment Of Leigh SyndromeApplication PCTUS2023068145Pending
  • Frataxin-sensitive Lipid Markers For Monitoring Frataxin Replacement TherapyApplication PCTUS2023066852Pending

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .